Race Oncology Limited (ASX:RAC)

Market Cap	611.17M
Revenue (ttm)	6.04M
Net Income (ttm)	-4.79M
Shares Out	176.64M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	169,042
Average Volume	361,063
Open	3.410
Previous Close	3.390
Day's Range	3.280 - 3.460
52-Week Range	0.920 - 4.900
Beta	1.10
RSI	47.66
Earnings Date	Nov 25, 2025

About Race Oncology

Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments in Australia. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RAC

Financial Performance

In 2025, Race Oncology's revenue was 6.04 million, an increase of 24.96% compared to the previous year's 4.84 million. Losses were -4.79 million, -65.36% less than in 2024.